Author: Sadikot, Ruxana T.; Kolanjiyil, Arun V.; Kleinstreuer, Clement; Rubinstein, Israel
Title: Nanomedicine for Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome Document date: 2017_6_27
ID: 27gutwjd_16
Snippet: We recently tested the efficacy of GLP-1 nanomicelles in a mouse model of lipopolysaccharide (LPS)-induced lung injury [16, 18, 36] . Mice (8 weeks old) were treated with LPS nebulization (concentration of 1 mg/mL) administered via a DeVilbiss disposable nebulizer (at a continuous air flow rate of 10 ft 3 /h) over 1 h to induce ALI. SSM treatment was administered via a subcutaneous route at a dose of 15 nmol of GLP-1/mouse. Control mice were trea.....
Document: We recently tested the efficacy of GLP-1 nanomicelles in a mouse model of lipopolysaccharide (LPS)-induced lung injury [16, 18, 36] . Mice (8 weeks old) were treated with LPS nebulization (concentration of 1 mg/mL) administered via a DeVilbiss disposable nebulizer (at a continuous air flow rate of 10 ft 3 /h) over 1 h to induce ALI. SSM treatment was administered via a subcutaneous route at a dose of 15 nmol of GLP-1/mouse. Control mice were treated with SSM with scrambled peptide or empty SSM. Mice received LPS through nebulization (1 mg/mL). We have previously shown that this model induces neutrophilic influx in the lung. To assess the magnitude of lung inflammation, total and neutrophil cell counts, proinflammatory cytokine levels (TNF-α, IL-6), total and neutrophil counts in bronchoalveolar lavage fluid, and myeloperoxidase activity in lung tissue were measured [16, 37] . In vivo administration of GLP-1-SSM to LPS-induced ALI mice resulted in significant downregulation of lung inflammation, with dose-dependent anti-inflammatory activity observed. Similar therapeutic activity was not detected for GLP-1 in saline, indicating that the SSM nanocarriers played a critical role in protecting the enzyme-labile GLP-1 and delivering it to inflamed tissues in vivo. This study demonstrated for the first time that the lipid-based nanoformulation of GLP-1 is effective at attenuating inflammation in ALI/ARDS [16] .
Search related documents:
Co phrase search for related documents- lung inflammation and myeloperoxidase activity: 1, 2, 3, 4, 5, 6, 7
- lung inflammation and neutrophil total: 1, 2
- lung inflammation and neutrophil total count: 1
- lung inflammation and significant downregulation: 1
- lung inflammation and therapeutic activity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- lung inflammation and TNF α cytokine level: 1
- lung inflammation and vivo administration: 1, 2, 3, 4
- lung injury and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- lung injury and myeloperoxidase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- lung injury and neutrophil total: 1, 2, 3, 4, 5
- lung injury and neutrophil total count: 1
- lung injury and significant downregulation: 1
- lung injury and therapeutic activity: 1, 2, 3, 4, 5, 6
- lung injury and vivo administration: 1
- lung tissue and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
- lung tissue and myeloperoxidase activity: 1, 2, 3, 4, 5
- lung tissue and significant downregulation: 1, 2
- lung tissue and vivo administration: 1, 2
- lung tissue myeloperoxidase activity and myeloperoxidase activity: 1, 2
Co phrase search for related documents, hyperlinks ordered by date